February I, 2025

One concern with bispecific antibody therapies in community settings is managing adverse events, with emerging patterns guiding management strategies.

Ado-trastuzumab emtansine led to improved overall survival and invasive disease–free survival over trastuzumab in patients with HER2-positive early breast cancer who had residual invasive disease after neoadjuvant therapy.

Chemoradiation with platinum-based chemo is standard for locally advanced cervical cancer, but adverse events drive exploration of immunotherapy and optimal treatment sequences.

Negative language about patients can reduce clinician empathy and recall of critical health details, a recent study finds.

ASH 2024 featured practice-changing studies in lymphoid malignancies, including tafasitamab’s impact in FL, ibrutinib’s OS benefit in MCL, and promising epcoritamab data in CLL.